(Bloomberg) -- Johnson & Johnson started a trial of its experimental Ebola vaccine in the U.K. and said it will produce 2 million courses of the shot this year.
The first volunteers in Oxford have received an initial dose, and the trial aims to recruit 72 people by the end of January, the New Brunswick, New Jersey-based company said in a statement today. Other tests are planned for the U.S., Kenya, Uganda and Tanzania. J&J has produced more than 400,000 courses of vaccine for use in large-scale trials by April, and could produce as many as 5 million courses over 12 to 18 months.
Drugmakers are racing to develop a protective vaccine against Ebola to curb the outbreak that has struck more than 20,000 people and killed more than 8,000, according to the World Health Organization. While the epidemic has stabilized in Liberia and Guinea, transmission remains intense in Sierra Leone, where more than 300 new infections were diagnosed in the last week of the year.
Recommended For You
Want to continue reading?
Become a Free PropertyCasualty360 Digital Reader
Your access to unlimited PropertyCasualty360 content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
